Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

12-week, double-blind, double-dummy, placebo-controlled, parallel-group, multicenter trial to evaluate the efficacy and safety of fesoterodine in comparison to tolterodine extended-release (ER) in patients with overactive bladder

Next Previous
X
Search
Trial Profile

12-week, double-blind, double-dummy, placebo-controlled, parallel-group, multicenter trial to evaluate the efficacy and safety of fesoterodine in comparison to tolterodine extended-release (ER) in patients with overactive bladder

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 20 Jan 2022

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fesoterodine (Primary) ; Tolterodine
  • Indications Overactive bladder
  • Focus Registrational; Therapeutic Use
  • Sponsors Pfizer

    • Most Recent Events

    • 31 Aug 2018 Results (n=6689) of pooled analysis from 6 studies (A0221008, A0221012, A0221013, A0221046, A0221094, A0221095) characterising patient symptom response resented at the 48th Annual Meeting of the International Continence Society
    • 31 Aug 2018 Results (n=6689) of pooled analysis from 6 studies (A0221008, A0221012, A0221013, A0221046, A0221094, A0221095) examining efficacy and safety presented at the 48th Annual Meeting of the International Continence Society
    • 31 Aug 2018 Results (n=6689) of pooled analysis from 6 studies (A0221008, A0221012, A0221013, A0221046, A0221094, A0221095) examing the relationship between disease variable resolution end of 4, 8 or 12 weeks treatment with fesoterodine and the proportion of patients achieving a significant improvement in Patient Reported Outcome Measures (PROM) resented at the 48th Annual Meeting of the International Continence Society

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top